Premium
Human lymphoblastoid interferon does not increase survival when added to mitozantrone in the treatment of hepatocellular carcinomas
Author(s) -
BROOK M. G.,
DUNK A. A.,
McDONALD J. A.,
LEVER A. M. L.,
GOH C.,
THOMAS H. C.
Publication year - 1987
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1987.tb00631.x
Subject(s) - hepatocellular carcinoma , medicine , interferon , lymphoblast , gastroenterology , carcinoma , oncology , interferon alfa , alpha interferon , immunology , cell culture , biology , genetics
SUMMARY Human lymphoblastoid interferon, in an initial dose of 2.5 MU m −2 weekly i.m., was given with mitozantrone 12 mg m −2 i.v. every 3 weeks to 15 patients with hepatocellular carcinoma. The survival curve for these patients was worse than that of 15 patients previously treated with mitozantrone alone; there were more long‐term survivors in those not given interferon; more side‐effects were seen in the group given interferon. The addition of interferon to mitozantrone in the management of hepatocellular carcinoma is not recommended.